MX355671B - Piridopirazinas como inhibidores novedosos de ptk. - Google Patents

Piridopirazinas como inhibidores novedosos de ptk.

Info

Publication number
MX355671B
MX355671B MX2013014242A MX2013014242A MX355671B MX 355671 B MX355671 B MX 355671B MX 2013014242 A MX2013014242 A MX 2013014242A MX 2013014242 A MX2013014242 A MX 2013014242A MX 355671 B MX355671 B MX 355671B
Authority
MX
Mexico
Prior art keywords
syk inhibitors
novel syk
pyridopyrazines
substituted
substituted pyridopyrazines
Prior art date
Application number
MX2013014242A
Other languages
English (en)
Other versions
MX2013014242A (es
Inventor
Su Wei-Guo
Deng Wei
Ji Jianguo
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX355671(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of MX2013014242A publication Critical patent/MX2013014242A/es
Publication of MX355671B publication Critical patent/MX355671B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Conductive Materials (AREA)

Abstract

Se proveen compuestos de piridopirazina de la fórmula (I), sus composiciones farmacéuticas y los métodos de uso para ellos; donde R1, R2, R3, R4 y m son como se definen en la descripción (VER Formula).
MX2013014242A 2011-06-08 2012-06-07 Piridopirazinas como inhibidores novedosos de ptk. MX355671B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2011/075431 WO2012167423A1 (en) 2011-06-08 2011-06-08 Substituted pyridopyrazines as novel syk inhibitors
PCT/CN2012/076576 WO2012167733A1 (en) 2011-06-08 2012-06-07 Substituted pyridopyrazines as novel syk inhibitors

Publications (2)

Publication Number Publication Date
MX2013014242A MX2013014242A (es) 2014-04-14
MX355671B true MX355671B (es) 2018-04-26

Family

ID=47295336

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014242A MX355671B (es) 2011-06-08 2012-06-07 Piridopirazinas como inhibidores novedosos de ptk.

Country Status (32)

Country Link
US (2) US9434726B2 (es)
EP (1) EP2718293B1 (es)
JP (2) JP5940148B2 (es)
KR (1) KR101571720B1 (es)
CN (1) CN103596952B (es)
AU (1) AU2012266941B2 (es)
BR (1) BR112013031405B1 (es)
CA (1) CA2836227C (es)
CL (1) CL2013003512A1 (es)
CY (1) CY1119953T1 (es)
DK (1) DK2718293T3 (es)
ES (1) ES2657549T3 (es)
HR (1) HRP20180139T1 (es)
HU (1) HUE037934T2 (es)
IL (1) IL229410A (es)
LT (1) LT2718293T (es)
MX (1) MX355671B (es)
MY (1) MY186599A (es)
NO (1) NO2718293T3 (es)
PE (1) PE20141167A1 (es)
PH (1) PH12013502434A1 (es)
PL (1) PL2718293T3 (es)
PT (1) PT2718293T (es)
RS (1) RS56901B1 (es)
RU (1) RU2569635C9 (es)
SG (1) SG195035A1 (es)
SI (1) SI2718293T1 (es)
SM (1) SMT201800057T1 (es)
TW (1) TWI494311B (es)
UA (1) UA111744C2 (es)
WO (2) WO2012167423A1 (es)
ZA (1) ZA201308947B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507458A (ja) * 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
WO2014028479A1 (en) 2012-08-13 2014-02-20 Envoy Therapeutics, Inc. Quinoxaline derivatives as gpr6 modulators
WO2014086032A1 (en) * 2012-12-07 2014-06-12 Hutchison Medipharma Limited Substituted pyridopyrazines as syk inhibitors
US10179783B2 (en) 2014-02-14 2019-01-15 Taketa Pharmaceutical Company Limited Tetrahydropyridopyrazines as modulators of GPR6
KR102431017B1 (ko) 2014-03-19 2022-08-11 베링거 인겔하임 인터내셔날 게엠베하 헤테로아릴 syk 억제제
AU2016280255A1 (en) 2015-06-18 2018-02-08 Cephalon, Inc. 1, 4-substituted piperidine derivatives
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
CN105153211B (zh) * 2015-09-22 2017-02-01 上海晋鲁医药科技有限公司 一种合成1‑(N‑Boc‑4‑哌啶)‑4‑吡唑硼酸频哪醇酯的方法
CN110072865B (zh) 2017-02-08 2022-02-11 中国医药研究开发中心有限公司 吡咯并芳杂环类化合物及其制备方法和医药用途
AU2018302026B2 (en) * 2017-07-18 2022-04-07 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
CN109422741A (zh) * 2017-08-22 2019-03-05 和记黄埔医药（上海）有限公司 化合物的盐及其晶型
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230043955A (ko) * 2020-07-23 2023-03-31 시토신랩 테라퓨틱스 코., 엘티디. 키나아제 억제 활성을 갖는 화합물
TW202313608A (zh) * 2021-06-04 2023-04-01 美商建南德克公司 ２，８—二氮雜螺［４．５］癸烷化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022779A (en) * 1974-07-25 1977-05-10 E. R. Squibb & Sons, Inc. Amino derivatives of pyrido(3,4-b)pyrazine carboxylic acids and esters
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP4903997B2 (ja) * 2002-07-02 2012-03-28 サザン リサーチ インスティチュート ＦｔｓＺの阻害剤およびそれらの用途
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
RU2515944C9 (ru) * 2005-11-11 2014-07-20 Этерна Центарис ГмбХ ПРОИЗВОДНЫЕ ПИРИДОПИРАЗИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ФИЗИОЛОГИЧЕСКИХ И/ИЛИ ПАТОФИЗИОЛОГИЧЕСКИХ СОСТОЯНИЙ ПОСРЕДСТВОМ ИНГИБИРОВАНИЯ ФЕРМЕНТОВ ERK, ERK1, ERK2, PI3K, PI3Kальфа, PI3Kбета, PI3Kгамма, PI3Kдельта, PI3K-С2альфа, PI3K-С2бета, PI3K-Vps34р (ВАРИАНТЫ)
TW200938542A (en) * 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
WO2010015520A1 (de) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
US8722692B2 (en) * 2009-07-30 2014-05-13 Jianwei Che Compounds and compositions as Syk kinase inhibitors
PT2477987T (pt) * 2009-09-14 2018-03-13 Gilead Sciences Inc Moduladores de recetores do tipo toll
KR20120125267A (ko) 2010-01-29 2012-11-14 베링거 인겔하임 인터내셔날 게엠베하 치환된 나프티리딘 및 ｓｙｋ 키나제 억제제로서의 이의 용도
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
JP2014507458A (ja) * 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
KR101986484B1 (ko) 2011-07-26 2019-06-10 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴놀린 및 이의 약제로서의 용도

Also Published As

Publication number Publication date
IL229410A (en) 2017-08-31
RU2013158996A (ru) 2015-07-20
US10052330B2 (en) 2018-08-21
EP2718293A1 (en) 2014-04-16
HK1190143A1 (zh) 2014-06-27
ES2657549T3 (es) 2018-03-05
NO2718293T3 (es) 2018-03-24
SI2718293T1 (en) 2018-04-30
UA111744C2 (uk) 2016-06-10
PH12013502434A1 (en) 2014-01-13
HUE037934T2 (hu) 2018-09-28
CA2836227A1 (en) 2012-12-13
WO2012167733A1 (en) 2012-12-13
HRP20180139T1 (hr) 2018-05-18
RS56901B1 (sr) 2018-05-31
IL229410A0 (en) 2014-01-30
JP6175484B2 (ja) 2017-08-02
CN103596952B (zh) 2016-05-04
RU2569635C2 (ru) 2015-11-27
JP2016106100A (ja) 2016-06-16
BR112013031405B1 (pt) 2021-12-21
ZA201308947B (en) 2020-02-26
KR20140025559A (ko) 2014-03-04
CY1119953T1 (el) 2018-12-12
SG195035A1 (en) 2013-12-30
PT2718293T (pt) 2018-01-30
US20140121200A1 (en) 2014-05-01
JP5940148B2 (ja) 2016-06-29
AU2012266941A1 (en) 2013-11-28
LT2718293T (lt) 2018-02-12
CN103596952A (zh) 2014-02-19
BR112013031405A2 (pt) 2016-12-06
TWI494311B (zh) 2015-08-01
EP2718293B1 (en) 2017-10-25
KR101571720B1 (ko) 2015-11-25
MY186599A (en) 2021-07-29
MX2013014242A (es) 2014-04-14
RU2569635C9 (ru) 2016-07-10
US20160324864A1 (en) 2016-11-10
DK2718293T3 (da) 2018-01-29
EP2718293A4 (en) 2014-12-03
PE20141167A1 (es) 2014-09-03
CL2013003512A1 (es) 2014-07-18
CA2836227C (en) 2016-08-16
JP2014516059A (ja) 2014-07-07
WO2012167423A1 (en) 2012-12-13
US9434726B2 (en) 2016-09-06
TW201305160A (zh) 2013-02-01
NZ617765A (en) 2016-02-26
PL2718293T3 (pl) 2018-05-30
SMT201800057T1 (it) 2018-03-08
AU2012266941B2 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
MY169043A (en) New dihydroquinoline-2-one derivatives
IN2014MN02598A (es)
PH12015500263A1 (en) New bicyclic derivatives
MY177344A (en) Compounds and their methods of use
PH12014501488A1 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
MX336381B (es) Boronatos como inhibidores de arginasa.
PH12014502169A1 (en) N-cyclylamides as nematicides
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
MY169267A (en) New aryl-quinoline derivatives
PH12014500584A1 (en) New bicyclic dihydroquinoline-2-one derivatives
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
IN2015DN01119A (es)
PH12015500399A1 (en) Azaindolines
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
MX2013003498A (es) Derivados de cromeno.
IN2015DN00950A (es)
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX344429B (es) Nuevos compuestos de hexahidropirroloimidazolona.
MX2014008856A (es) Derivados de imidazolilcetona como inhibidores de aldosterona sintasa.
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors

Legal Events

Date Code Title Description
FG Grant or registration